SEM in Motion: Select Medical Q1 2026 earnings, cash bid, and a merger countdown

Select Medical Holdings Corporation (NYSE: SEM) reported its first quarter results for the period ended March 31, 2026, with revenue up 5.0% year over year to about $1.42 billion. Net income reached $63.8 million, while earnings per common share came in at $0.35 on a GAAP basis and $0.36 on an adjusted basis. Adjusted EBITDA was $141.6 million, and the press release notes that the company provides reconciliations for these figures in its tables. No explicit earnings surprise was disclosed in the release, and the document references an ongoing effort to align earnings metrics with non-GAAP measures.

The quarter’s fundamentals sit in a familiar framework for SEM: a diversified post-acute care platform with three reportable segments—Critical Illness Recovery Hospital, Rehabilitation Hospital, and Outpatient Rehabilitation. The company also disclosed a broad footprint: 103 critical illness recovery hospitals in 28 states, 41 rehabilitation hospitals in 15 states, and 1,912 outpatient rehabilitation clinics across 37 states and the District of Columbia, with operations in 38 states plus DC as of March 31, 2026. Information about the company remains available at its website.

On the corporate action front, SEM announced a merger agreement with wholly owned subsidiaries of Welsh, Carson, Anderson & Stowe (WCAS XIV, L.P.) and a consortium led by Robert Ortenzio and Martin Jackson. The deal proposes a cash consideration of $16.50 per share for each issued and outstanding share of SEM, subject to customary exceptions. The merger would leave SEM as a wholly owned subsidiary of the buyer group, with delisting from the NYSE and deregistration under the Exchange Act upon completion.

First quarter highlights

• Revenue: $1,421.5 million, up 5.0% versus the prior-year quarter.
• Net income: $63.8 million.
• EPS (GAAP): $0.35; Adjusted EPS: $0.36.
• Adjusted EBITDA: $141.6 million; the report emphasizes a reconciliation framework for these non-GAAP measures.
• Guidance: The release does not provide a forward-looking revenue forecast in this press release, focusing instead on quarter-to-quarter performance and the merger timing.

The company draws attention to the reconciliations of Adjusted EBITDA and adjusted earnings per share in Table VI and VII of the release. These disclosures aim to help readers compare performance across periods, a nod to the ongoing emphasis on non-GAAP metrics in healthcare services.

Segment detail: where the money came from

Critical Illness Recovery Hospital Segment: Revenue of $638.8 million, up 0.3% from the prior year quarter. Adjusted EBITDA was $73.4 million, down from $86.6 million in the prior-year quarter. Margin was 11.5%, trailing the prior-year level of 13.6%.

Rehabilitation Hospital Segment: Revenue of $351.9 million, up 14.5% year over year. Adjusted EBITDA rose to $81.1 million from $70.4 million, with an EBITDA margin of 23.0% for the quarter (versus the prior year).

Outpatient Rehabilitation: The press release centers the segment-level results on the two larger hospital segments and notes overall multi-segment performance, but the segment detail clearly illustrates continued revenue growth in rehabilitation services, even as the critical illness recovery segment shows margin pressure.

The company tallies its footprint and operating reach to highlight scale gains in outpatient clinics and hospital networks, underscoring why positioning in the post-acute care market matters to investors, staff, and acuity mix management alike.

Merger agreement: a potential pivot point

The proposed merger contemplates a cash merger at $16.50 per share, delivering immediate value to shareholders but placing SEM under the control of the WCAS-led buyer group. Key timing notes: the Hart-Scott-Rodino waiting period expired on April 27, 2026; closing remains contingent on regulatory approvals, stockholder approval (including a majority not held by the buyer group or affiliates), and other customary closing conditions. Management cautions that the timing is uncertain and that there can be no assurance of completion in mid-2026 or at all.

If the merger completes, SEM’s shares would be delisted from the NYSE and deregistered under the Exchange Act. The deal reflects a persistent theme in healthcare and services: private equity and strategic buyers testing the structural fit and capitalization of public mid-cap platforms that come with scale in fragmented post-acute markets.

What this means for SEM and peers

SEM’s Q1 results show a company with solid top-line momentum in outpatient services and a rehabilitation segment that is delivering meaningful margin expansion. The erosion in the Critical Illness Recovery Hospital segment EBITDA margin suggests mix and cost dynamics that management will want to address, even as revenue continues to grow. The looming delisting post-merger would remove SEM from public market price discovery, shifting investor focus toward operational execution, integration risk, and the strategic rationale of the buyer group.

For sector peers, the SEM move underscores how large privately negotiated buyouts or sponsor-led reformulations of post-acute platforms could become a more common exit path. If the merger closes as proposed, it may reinforce a view that scale and private ownership offer a more predictable capital structure for this business line, potentially shaping M&A activity, capital allocation, and dividend policies across the broader EMS/post-acute landscape.

Takeaways

• SEM remains a sizable operator in the post-acute care ecosystem, with a diversified mix that includes critical illness recovery, rehabilitation, and outpatient services.
• The Q1 2026 results show revenue growth but mixed EBITDA margins by segment, signaling ongoing optimization opportunities in capital intensity and patient mix.
• The $16.50 per share merger offer represents a strategic pivot point; execution depends on regulatory clearances and stockholder approvals. If completed, SEM would transition from a public reporting company to a privately controlled platform under WCAS XIV and its partners.
• Analysts will likely compare GAAP EPS and Adjusted EPS against consensus expectations, watching for any implied shifts in margin structure and cash-flow generation under a potential new parent ownership.
• In the near term, the market will gauge the bid’s certainty, the timetable for closing, and how the post-merger corporate strategy would affect investment in hospital networks, outpatient clinics, and the long-run revenue forecast for the platform.

Bottom line: SEM’s quarter is a reminder that in healthcare services, the pace of patient volumes and service mix can outpace headline revenue growth, while the real strategic move may come from who ultimately owns the asset and how quickly the combination can unlock value. For investors watching EPS benchmarks and the trajectory of EBITDA margins, the merger narrative adds a new variable to the standard earnings calculus.